Bispecific Antibody Therapeutics Market (2nd Edition), 2014 - 2024

DUBLIN, Dec. 09, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/9n5sj5/bispecific) has announced the addition of the "Bispecific Antibody Therapeutics Market (2nd Edition), 2014 - 2024" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The concept of bispecific antibodies is increasingly gaining traction in the pharma industry owing to several therapeutic advantages and their potential to address challenges known with the monoclonal antibody based therapies. Bispecific antibodies are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

The market is still in its infancy. With the EMA approval for Removab in 2009 and recent filing for blinatumomab, a great deal of interest has been generated in the bispecific antibody market. The pipeline, which is rich and diverse, has drugs being developed for both oncological and non-oncological indications. These drugs are based on about 50 different technological platforms developed by companies such as Trion Pharma, Amgen, AbbVie, Ablynx, Affimed and MacroGenics amongst others. The platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system.

During the course of our research, we came across 37 molecules currently in different stages of clinical development. Over 75% of these molecules are industry sponsored and we expect around 8-9 of them to be launched by the end of this decade, providing the much needed push to this market. In addition to the clinical pipeline, we have identified over 70 molecules which are currently in preclinical / discovery phase. Technological advancements, especially in the purification of bispecific antibodies will ensure the development of products with improved safety, potency and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

The 2nd edition of the Bispecific Antibody Therapeutics Market, 2014-2024 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.

The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. These drugs are being developed for both oncological as well as non-oncological indications. The report highlights various companies which are active in the market and discusses, in detail, the underlying technologies which form the basis of many of the pipeline drugs.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES

5. CURRENT MARKET AND FORECAST

6. TECHNOLOGY PLATFORMS

7. PARTNERSHIPS: BACKBONE OF THE GROWING BISPECIFIC INDUSTRY

8. PROFILES OF LEADING COMPANIES

9. SWOT ANALYSIS

10. INTERVIEW TRANSCRIPTS

11. CONCLUSIONS

12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS

13. APPENDIX 2: TABULATED DATA

For more information visit http://www.researchandmarkets.com/research/9n5sj5/bispecific

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets